Form 8-K ImmunityBio, Inc. For: Aug 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day losing streak as stocks reclaim some shine
- Oil rises 1%, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
ImmunityBio's (IBRX) NantCell Statement on Sorrento's (SCLX) Failure to Pay Settlement
September 1, 2023 8:40 AM EDTAs previously disclosed, on August 14, 2023, the United States Bankruptcy Court for the Southern District of Texas issued an order approving the settlement involving Sorrento Therapeutics, Inc.s (Sorrento) litigation claims against ImmunityBio (NASDAQ: IBRX) wholly-owned subsidiary NantCell, Inc. (NantCell) and others, such that the settlement is binding on the parties. The settlement is described in detail in the motion filed with the bankruptcy court on June 6, 2023 in In re... More
